en · de · es · fr · pt
bench-notes.peptides6088.com › Topic › Research And Regulatory Context — Practical Notes

Research And Regulatory Context — Practical Notes

By Editorial Desk · published 2025-11-29 · last reviewed 2025-12-24 · Topic

The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.

Research and Regulatory Context

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineMajor agencies have not authorized it for therapeutic use.
Anti-doping statusProhibited in sportListed among peptide hormones and related substances.
Primary research areaMetabolic and body-composition effectsStudies often examine fat mass or lipid markers.
Human evidenceLimited and mixedPublic data do not establish clinical efficacy.
Analytical detectionLC-MS and immunoassaysMethods vary in sensitivity and validation.

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Related pages on this site

Identity and Research Context

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Background from the literature

Melanotan-II may cause reversible darkening of moles and freckles. It is unclear if Melanotan II can increase (or reduce) the risk of developing melanoma. Reports of melanomas associated with the use of Melanotan II have coincided with heavy sunbathing and sun bed use. A 2013 scientific review found there was no conclusive evidence it causes melanoma, and a 2021 review concluded "the increased risk of melanoma in Melanotan users, who use it for tanning and exhibit sun-seeking behaviour, can probably be explained by more UV exposure". A 2020 in vivo study found that Melanotan II suppressed the progression of melanomas.

horizontal gene transfer (HGT) Also lateral gene transfer (LGT). Any process by which genetic material is transferred between unicellular and/or multicellular organisms other than by vertical transmission from parent to offspring, e.g. bacterial conjugation.

The [pharmaceutical] industry has taken advantage of the incentives to charge excessive profits and to reap windfalls far in excess of their investments in the drug. Provigil was an orphan drug and went on to be a blockbuster.

Sources: en.wikipedia.org

Reference notes

κ-Bungarotoxin (kappa-bungarotoxin) is a neurotoxin that is part of the bungarotoxin family. The neurotoxin can be found in the venom of the many-banded krait (Bungarus multicinctus). This snake species can be found in China, Myanmar, Laos, North Vietnam and Thailand. The toxin attacks the neuronal nicotinic acetylcholine receptors, inhibiting neurotransmission. Even though a snake bite of this species is rare, they do have a case-fatality range from 7% to 50%. Death can occur between 6 and 30 hours after a Bungarus multicinctus snakebite.

Transgender people face various kinds of discrimination, especially in health care situations. An assessment of transgender needs in Philadelphia found that 26% of respondents had been denied health care because they were transgender and 52% of respondents had difficulty accessing health services. Aside from transition related care, transgender and gender non-conforming individuals need preventive care such as vaccines, gynecological care, prostate exams, and other annual preventive health measures. Various factors play a role in creating the limited access to care, such as insurance coverage issues related to their legal gender identity status. The Affordable Care Act (commonly known as Obamacare) marketplace has improved access to insurance for the LGBTQ community through anti-discriminatory measures, such as not allowing insurance companies to reject consumers for being transgender. However, insurance sold outside of the ACA marketplace does not have to follow these requirements. This means that preventive care, such as gynecological exams for transgender men, may not be covered. Starting in the early-2020s, as many as 13 U.S. states banned gender affirming health care for transgender youth, with several states further restricting treatment for adults as well. In January 2024, several Republican legislators have expressed their desire to ban gender-affirming healthcare altogether.

== External links == Media related to Earthworms at Wikimedia Commons Data related to Lumbricina at Wikispecies Chisholm, Hugh, ed. (1911). "Earthworm" . Encyclopædia Britannica (11th ed.). Cambridge University Press.

=== Deformed nuclei === Though nuclei within the island of stability around N = 184 are predicted to be spherical, studies from the early 1990s—beginning with Polish physicists Zygmunt Patyk and Adam Sobiczewski in 1991—suggest that some superheavy elements do not have perfectly spherical nuclei. A change in the shape of the nucleus changes the position of neutrons and protons in the shell. Research indicates that large nuclei farther from spherical magic numbers are deformed, causing magic numbers to shift or new magic numbers to appear. Current theoretical investigation indicates that in the region Z = 106–108 and N ≈ 160–164, nuclei may be more resistant to fission as a consequence of shell effects for deformed nuclei; thus, such superheavy nuclei would only undergo alpha decay. Hassium-270 is now believed to be a doubly magic deformed nucleus, with deformed magic numbers Z = 108 and N = 162. It has a half-life of 9 seconds. This is consistent with models that take into account the deformed nature of nuclei intermediate between the actinides and island of stability near N = 184, in which a stability "peninsula" emerges at deformed magic numbers Z = 108 and N = 162. Determination of the decay properties of neighboring hassium and seaborgium isotopes near N = 162 provides further strong evidence for this region of relative stability in deformed nuclei.

Sources: en.wikipedia.org

Reference notes

=== Bacteria and archaea === Vitamin B12 is produced in nature by certain bacteria and archaea. It is synthesized by some bacteria in the gut microbiota in humans and other animals, but it has long been thought that humans cannot absorb this as it is made in the colon, downstream from the small intestine, where the absorption of most nutrients occurs. Ruminants, such as cows and sheep, are foregut fermenters, meaning that plant food undergoes microbial fermentation in the rumen before entering the true stomach (abomasum), thus allowing them to absorb the vitamin B12 produced by the bacteria. Other mammalian species (examples: rabbits, pikas, beaver, guinea pigs) consume high-fiber plants which pass through the gastrointestinal tract and undergo bacterial fermentation in the cecum and large intestine. In this hindgut fermentation, the material from the cecum is expelled as "cecotropes" and are re-ingested, a practice referred to as cecotrophy. Re-ingestion allows for absorption of nutrients made available by bacterial fermentation, and also of vitamins and other nutrients synthesized by the gut bacteria, including vitamin B12. Non-ruminant, non-hindgut herbivores may have an enlarged forestomach and/or small intestine to provide a place for bacterial fermentation and B-vitamin production, including B12. For gut bacteria to produce vitamin B12, the animal must consume sufficient amounts of cobalt. Soil that is deficient in cobalt may result in B12 deficiency, and B12 injections or cobalt supplementation may be required for livestock.

=== Addiction and dependence === Although classified as a central nervous system (CNS) stimulant, the addiction and dependence liabilities of modafinil are considered low. The exact mechanisms of action of modafinil are not known, and its pharmacological profile differs from that of the classical stimulants such as cocaine or amphetamine. Although modafinil shares biochemical mechanisms with stimulant drugs, it is less likely to have mood-elevating properties. The similarities in effects with caffeine are not clearly established. Unlike other stimulants, modafinil does not induce a strong subjective feeling of pleasure or reward or euphoria, which contributes to its lower abuse potential. Albeit to a lower degree than classical stimulants, modafinil still can produce psychoactive, euphoric, and subjective effects typical for abused stimulants. Despite initial assessments of low abuse potential, some evidence indicates modafinil acts on the same neurobiological mechanisms as other addictive stimulants, which is a reason for caution when prescribing. Modafinil scores lower than amphetamine on standardized abuse-potential assessments, suggesting reduced propensity for abuse. The US Drug Enforcement Administration has classified modafinil as a Schedule IV controlled substance; the medicine is recognized for having valid medical uses with low addiction potential. The International Narcotics Control Board does not classify it as a narcotic or a psychotropic substance.

=== 31 March === Seven people were killed by RSF shelling on the Abu Shouk camp. The RSF claimed to have taken Khor El Dalaib in South Kordofan following clashes that left 12 civilians dead. It also claimed to have killed 70 fighters of the Islamic Movement, and destroyed or captured 13 vehicles.

In atherosclerosis, new blood vessels form within plaques, contributing to their growth and instability. These vessels are often fragile, allowing inflammatory cells and fats to enter, which can cause bleeding inside the plaque and increase the risk of rupture. Some studies in animal models suggest that blocking this vessel growth can reduce atherosclerotic progression. In a myocardial infarction, blocked blood flow deprives heart tissue of oxygen, leading to cell damage. Neovascularization in the surrounding area can help restore oxygen supply and limit further injury. Growth factors such as basic fibroblast growth factor (bFGF) and brain natriuretic peptide (BNP) can promote angiogenesis after an acute MI. Following a stroke, ischemic penumbra (the region surrounding the infarct core) can disrupt the cerebral blood flow. Post-stroke angiogenesis in the area helps restore perfusion and supports neurological recovery. Additionally, arteriogenesis contributes to post-stroke blood flow restoration. Various immune cells and cytokines play a role in regulating angiogenesis after ischemic injury.

=== Tahini's === Tahini's is a fast-casual Mediterranean and Middle Eastern fusion restaurant chain founded in London, Ontario, in 2012 by Omar Hamam. The chain is known for blending traditional shawarma with international cuisine, featuring items such as butter chicken shawarma, Jamaican jerk shawarma, and shawarma ramen. As of 2026, Tahini's operates over 70 locations across Canada and has begun expanding into international markets including the United States.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.

Why is AOD-9604 banned in sports?

It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.

What do human studies show?

Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

Network